There is a significant correlation between plasma levels of lipoprotein (Lp)(a), coronary artery disease, and the severity of atherosclerosis. The overall objective of this research is to develop a diagnostic test for Lp(a) by developing immunoassays specific for the Lp(a) antigen, apo(a). The remarkable overall sequence similarity between the Lp(a) antigen, apo(a), and the plasma protease plasminogen results in extensive immunological cross-reactivity. Currently available immunoassays are not specific for apo(a). Therefore, their suitability in assessing individual risk factors by quantitation of plasma Lp(a) levels appears questionable. The sequence similarity of apo(a) and plasminogen presents major problems for monospecific antibody production. Genetic Profiles' strategy involves the use of synthetic peptides corresponding to unique regions of apo(a) that do not occur in plasminogen. Antibodies raised against these peptides will be used to develop a sensitive and specific assay for Lp(a) levels and the apo(a) isoforms. These assays will be utilized commercially as part of a panel of tests for the evaluation of relative risk for atherosclerosis. In addition, the synthetic peptides will be evaluated as chemically defined standards for these assays. The antibodies, specific for defined regions of apo(a), should also be useful for structural, biological, and pathological studies of the Lp(a) antigen.
Anticipated Results:The goal of this research is to develop a specific and sensitive assay for Lp(a), an important risk factor in atherosclerosis. The assay, after validation and clinical correlation, will be offered commercially to clinicians for assessment of relative risk of atherosclerosis associated with Lp(a).National Heart, Lung, And Blood Institute (NHLBI)
